Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.13 +0.04 (0.14%) 9:14 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.13 +0.04 (0.14%) 9:14 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pfizer (PFE) Tests COVID-19 Booster & Pneumococcal Vaccine Combo
by Zacks Equity Research
Pfizer's (PFE) study is testing its pneumococcal vaccine candidate along with COVID-19 booster shot on 600 fully vaccinated adults 60 years and older.
AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan
by Zacks Equity Research
AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.
Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.
Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.
Top Stock Reports for Mastercard, Home Depot & Walt Disney
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Mastercard Incorporated (MA), The Home Depot, Inc. (HD), and The Walt Disney Company (DIS).
Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
by Sweta Jaiswal, FRM
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.
PFE vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.
Stock Market News for May 7, 2021
by Zacks Equity Research
Wall Street closed sharply higher on Thursday following strong labor market Data.
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.
Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $39.95 in the latest trading session, marking a +0.3% move from the prior day.
Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.
Q1 Earnings Season Maintains its Momentum
by Zacks Equity Research
Q1 Earnings Season Maintains its Momentum.
Pfizer, UnderArmour Beat; Trade Deficit at All-Time Low
by Mark Vickery
A sense of caution has begun to permeate the market off near-all-time highs in the indexes, and Pfizer looks to be a recipient of this today.
Pfizer (PFE) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 17.72% and 8.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Gears for a Hectic Earnings Week
by Zacks Equity Research
Wall Street Gears for a Hectic Earnings Week.
Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.